pI: 5.7212 |
Length (AA): 414 |
MW (Da): 47121 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
29 | 363 | 1ezf (A) | 38 | 367 | 47.00 | 0 | 1 | 1.43 | -2.25 |
28 | 369 | 3wca (A) | 28 | 368 | 61.00 | 0 | 1 | 1.72619 | -1.95 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_129470)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G34640 | Squalene synthase 1 |
Arabidopsis thaliana | AT4G34650 | squalene synthase 2 |
Candida albicans | CaO19.11099 | squalene synthase similar to S. cerevisiae ERG9 (YHR190W) involved in ergosterol biosynthesis |
Candida albicans | CaO19.3616 | squalene synthase similar to S. cerevisiae ERG9 (YHR190W) involved in ergosterol biosynthesis |
Dictyostelium discoideum | DDB_G0292072 | farnesyl-diphosphate farnesyltransferase |
Homo sapiens | ENSG00000079459 | farnesyl-diphosphate farnesyltransferase 1 |
Leishmania braziliensis | LbrM.31.3310 | squalene synthase, putative |
Leishmania donovani | LdBPK_313050.1 | farnesyltransferase, putative |
Leishmania infantum | LinJ.31.3050 | squalene synthase, putative |
Leishmania major | LmjF.31.2940 | squalene synthase, putative |
Leishmania mexicana | LmxM.30.2940 | farnesyltransferase, putative |
Mus musculus | ENSMUSG00000021273 | farnesyl diphosphate farnesyl transferase 1 |
Oryza sativa | 4342663 | Os07g0200700 |
Oryza sativa | 4334492 | Os03g0805100 |
Saccharomyces cerevisiae | YHR190W | bifunctional farnesyl-diphosphate farnesyltransferase/squalene synthase |
Trypanosoma brucei gambiense | Tbg972.8.7370 | farnesyltransferase, putative,squalene synthase, putative |
Trypanosoma brucei | Tb927.8.7120 | squalene synthase, putative |
Trypanosoma congolense | TcIL3000_0_37460 | squalene synthase, putative |
Trypanosoma congolense | TcIL3000_8_7210 | squalene synthase, putative |
Trypanosoma congolense | TcIL3000_0_23140 | squalene synthase, putative |
Trypanosoma cruzi | TcCLB.507897.20 | squalene synthase, putative |
Trypanosoma cruzi | TcCLB.508369.20 | squalene synthase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.7120 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.7120 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.7120 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.7120 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
YHR190W | Saccharomyces cerevisiae | inviable | yeastgenome |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: (BPQ-OH) 136562-09-9 . chemical inhibition with squalene synthase (2.5.1.21) inhibitors leads to slow growth and membrane disruption of Leishmania sp. in cell assay; biphenylquinuclidine inhibitors. | References: | 16198340 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: (BPQ-OH) 136562-09-9 . chemical inhibition with squalene synthase (2.5.1.21) inhibitors leads to slow growth and membrane disruption of Leishmania sp. in cell assay; biphenylquinuclidine inhibitors. | References: | 16198340 | |
plasma membrane (GO:0005886) | disrupted (PATO:0001507) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from visible phenotype (ECO:0000176) | Leishmania amazonensis | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: (BPQ-OH) 136562-09-9 . chemical inhibition with squalene synthase (2.5.1.21) inhibitors leads to slow growth and membrane disruption of Leishmania sp. in cell assay; biphenylquinuclidine inhibitors. | References: | 16198340 | |
plasma membrane (GO:0005886) | disrupted (PATO:0001507) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from visible phenotype (ECO:0000176) | Leishmania amazonensis | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: (BPQ-OH) 136562-09-9 . chemical inhibition with squalene synthase (2.5.1.21) inhibitors leads to slow growth and membrane disruption of Leishmania sp. in cell assay; biphenylquinuclidine inhibitors. | References: | 16198340 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: (BPQ-OH) 136562-09-9 . chemical inhibition with squalene synthase (2.5.1.21) inhibitors leads to slow growth and membrane disruption of Leishmania sp. in cell assay; biphenylquinuclidine inhibitors. | References: | 12467972 15848765 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania mexicana | No drug identifiers listed for this gene. | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: (BPQ-OH) 136562-09-9 . chemical inhibition with squalene synthase (2.5.1.21) inhibitors leads to reduced enzyme activity in vitro; biphenylquinuclidine inhibitors. | References: | 12467972 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania donovani | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: (BPQ-OH) 136562-09-9 . chemical inhibition with squalene synthase (2.5.1.21) inhibitors leads to slow growth and membrane disruption of Leishmania sp. in cell assay; biphenylquinuclidine inhibitors. | References: | 15848765 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania major | No drug identifiers listed for this gene. | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: (BPQ-OH) 136562-09-9 . chemical inhibition with squalene synthase (2.5.1.21) inhibitors leads to reduced enzyme activity in vitro; biphenylquinuclidine inhibitors. | References: | 15848765 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | 149351 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 212519-41-0; Drug: 212519-47-6. chemical inhibition with PFT inhibitors leads to slow growth of Leishmania sp. in cell assay; . | References: | 9719512 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.8
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Trypanosoma cruzi | squalene synthase, putative | Compounds | References |
Homo sapiens | farnesyl-diphosphate farnesyltransferase 1 | Compounds | References |
Saccharomyces cerevisiae | bifunctional farnesyl-diphosphate farnesyltransferase/squalene synthase | Compounds | References |
Rattus norvegicus | Squalene synthetase | Compounds | References |
Bos taurus | Squalene synthetase | Compounds | References |
Trypanosoma cruzi | squalene synthase, putative | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Staphylococcus aureus | Dehydrosqualene synthase | 287 aa | 20.9% | 320 aa | Compounds | References |
7 literature references were collected for this gene.